Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19

Two Letters to Blood address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association be...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Peter G., Fell, Geoffrey G., Foy, Brody H., Scherer, Allison K., Gibson, Christopher J., Sperling, Adam S., Burugula, Bala B., Nakao, Tetsushi, Uddin, Md M., Warren, Hailey, Bry, Lynn, Pozdnyakova, Olga, Frigault, Matthew J., Bick, Alex G., Neuberg, Donna, Higgins, John M., Mansour, Michael K., Natarajan, Pradeep, Kim, Annette S., Kitzman, Jacob O., Ebert, Benjamin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: by The American Society of Hematology 2022
Materias:
Letter to Blood
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474399/
https://www.ncbi.nlm.nih.gov/pubmed/36096050
http://dx.doi.org/10.1182/blood.2022018052
Descripción
Sumario:Two Letters to Blood address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association between CHIP and 28-day mortality while providing data indirectly linking IL-6 signaling and patient outcomes. In the second article, Ho and colleagues investigate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS) with COVID-19, reporting that one-fourth had a severe infection and that on multivariable analysis, adverse outcomes are more likely if immunoparesis is present.

Ejemplares similares